Company Overview: Cantabio Pharmaceuticals

Industry News

13 Sep

Cantabio Pharmaceuticals to Present at 2017 Silicon Valley Bank Healthcare Capital and Connections Summit in Shanghai

SAN FRANCISCO, CA–(Marketwired – September 13, 2017) – Cantabio Pharmaceuticals, Inc. (CTBO), a biopharmaceutical company developing novel disease modifying therapies for Alzheimer’s, Parkinson’s and other related neurodegenerative diseases, today announced that its CEO, Dr Gergely Tóth, will present at the 2017 Silicon Valley Bank Healthcare Capital and Connections Summit in Shanghai,...

Read more

11 Sep

Cantabio announces publication of study on a mechanism by which the DJ-1 protein loses its defensive function in neurodegenerative disease conditions

SUNNYVALE, CA–(Marketwired – September 11, 2017) – Cantabio Pharmaceuticals, Inc. (CTBO) (“Cantabio” or the “Company”), a preclinical stage pharmaceutical company developing disease modifying therapeutics for Alzheimer’s Disease (AD), Parkinson’s Disease (PD) and related neurodegenerative diseases today announced a publication lead authored by Cantabio’s CEO Dr Gergely Tóth, along with collaborators at the...

Read more

26 Jul

Cantabio Pharmaceuticals

Cantabio Pharmaceuticals Inc. is a preclinical stage biotechnology company focusing on commercializing novel therapies and the intellectual property generated from our research and development activities for Parkinson’s disease (PD), Alzheimer’s disease (AD) and other related neurodegenerative diseases. Our strategy integrates a detailed therapeutic focus, target family biophysics, and drug...

Read more

Enter your email address to receive notifications of new posts by email.

Latest Tweets


Follow this blog

Get every new post delivered right to your inbox.

Email address